Mar 3 2010
VUCCC P/L is pleased to announce that it has filed for patent protection of its ground breaking new treatment regimen for Type 1 'insulin-dependent' diabetes, through the European Patent Office.
Developed with science emanating from collaborators at 4 European universities (Tübingen University, Heidelberg University, Manchester & Uppsala Universities), it is the result of over a decade of clinical trial work in with over 15,000 patients, carried out in conjunction with the German Ministry of Health and other partners.
VUCCC states that the treatment has cured the disease in more than 80% of sufferers treated and does not suffer a relapse during the first 24 months after successfully completing the treatment has remained disease free.
The treatment regimen is closely controlled in conjunction with the patient's doctor, guided by diagnostic testing proprietary to VUCCC. This development will see VUCCC establish diagnostic reference centres across Europe, to ascertain patients' potential treatment outcomes. VUCCC also states that it will establish a centralised teaching centre, for controlling the standard of the ongoing testing program.
The company estimates there will be an average long term saving to the German Ministry of Health of EUR 70 billion per year. The estimate is based on existing costs of patient management and the number of patients treatable with this technology.
VUCCC will have an agreement in place with a major pharmaceutical company and an international laboratory network for marketing, distribution, sales and related laboratory services for the treatment. It will be launched in Germany in 2010. Release in other countries will follow.
This development represents the next step in two years of commercialisation work between VUCCC P/L and P+S Business Advisory, a division of P + S Business Brokers, of Melbourne, Australia, in bringing this technology to market. Further patents are pending.
Global gap in diabetes prevalence and treatment has widened since 1990